Safety and efficacy of trastuzumab emtansine (TDM-1) in a patient on hemodialysis for renal failure
| Autor: | A. Sánchez Gastaldo, J. Salvador Boffil, A. Falcon Gonzalez, P. Estévez Garcia, I. Sánchez Simón, M. Ruiz Borrego |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Receptor ErbB-2 medicine.medical_treatment Breast Neoplasms Lapatinib Ado-Trastuzumab Emtansine 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Antineoplastic Agents Immunological Trastuzumab Renal Dialysis Internal medicine medicine Humans In patient 030212 general & internal medicine skin and connective tissue diseases Dialysis Trastuzumab emtansine RC254-282 Aged Dose-Response Relationship Drug business.industry Tdm-1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens Anemia medicine.disease Metastatic breast cancer Renal Elimination Treatment Outcome chemistry 030220 oncology & carcinogenesis Hemodialysis Kidney Failure Chronic Female Pertuzumab business medicine.drug |
| Zdroj: | Cancer Treatment and Research Communications, Vol 27, Iss, Pp 100314-(2021) |
| ISSN: | 2468-2942 |
| Popis: | HER2-positive metastatic breast cancer is an aggressive disease with a limited number of treatment options. In the last 15 years, new drugs such as trastuzumab, pertuzumab, lapatinib or trastuzumab emtansine (TDM-1) have sprouted for these patients. There is a huge lack of evidence on the use of some of these drugs in patients with chronic renal failure, who need hemodialysis. We have reviewed the use of TDM-1 in these type of patients in the literature with unsuccessful results. In this article we want to present a case report to illustrate the safety and efficacy of TDM-1 in a patient on hemodialysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect